| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Rifampin measurement |
Component |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Poisoning by rifampin |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Accidental rifampin poisoning |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Intentional rifampin poisoning (disorder) |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampin poisoning of undetermined intent |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin adverse reaction |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Allergy to rifampicin |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampin overdose (disorder) |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Accidental rifampin overdose |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Intentional rifampin overdose |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampin overdose of undetermined intent |
Causative agent (attribute) |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampicin 100mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| rifampicine 600 mg, solvant pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| rifampicine 300 mg, diluant pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Isoniazid + pyrazinamide + rifampin 50mg/300mg/120mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Product containing precisely isoniazid 100 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Product containing isoniazid and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing isoniazid and pyrazinamide and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Urine rifampicin level (procedure) |
Component |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Accidental rifampin poisoning |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Intentional rifampin poisoning (disorder) |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Isoniazid +rifampin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampicin-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Measurement of rifampin in serum specimen using high performance liquid chromatography |
Component |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Allergy to rifampicin |
Causative agent (attribute) |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing isoniazid and pyrazinamide and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing ethambutol and isoniazid and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Ethambutol- and isoniazid- and rifampicin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing ethambutol and isoniazid and pyrazinamide and rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Product containing ethambutol and isoniazid and pyrazinamide and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 100 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 100 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 100 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin sodium (substance) |
Is a |
False |
Rifampicin |
Inferred relationship |
Some |
|
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Rifampicin 300 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely rifampicin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 100 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin sodium (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Rifampicin |
Inferred relationship |
Some |
|
| Rifampicin 600 mg powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 600 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 20 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 20 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Ethambutol and isoniazid and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Ethambutol and isoniazid and pyrazinamide and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Isoniazid and pyrazinamide and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Isoniazid and rifampicin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing only rifampicin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Ethambutol and isoniazid and pyrazinamide and rifampicin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Product containing only ethambutol and isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing only isoniazid and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing only isoniazid and pyrazinamide and rifampicin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Ethambutol hydrochloride 275 mg and isoniazid 75 mg and rifampicin 150 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Ethambutol hydrochloride 275 mg and isoniazid 75 mg and rifampicin 150 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
2 |
| Isoniazid 150 mg and rifampicin 300 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and pyrazinamide 400 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Product containing precisely ethambutol hydrochloride 275 milligram and isoniazid 75 milligram and pyrazinamide 400 milligram and rifampicin 150 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
3 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Product containing precisely rifampicin 600 milligram/1 vial powder for conventional release solution for infusion and/or injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 150 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 150 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg powder for solution for infusion vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg powder for solution for infusion vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 450 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Rifampicin 450 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Isoniazid 75 mg and rifampicin 150 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Isoniazid 75 mg and rifampicin 150 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Chemical synovectomy using rifampicin |
Direct substance |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Measurement of rifampin in serum specimen using high performance liquid chromatography |
Component |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
| Urine rifampicin level (procedure) |
Component |
True |
Rifampicin |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]